Pancreatic digestive enzyme gene expression: effects of CCK and soybean trypsin inhibitor.
Regulation of pancreatic gene expression by cholecystokinin (CCK) was examined in the rat using cloned cDNA probes to quantify changes in specific mRNAs (amylase, trypsinogen I, chymotrypsinogen B, and ribonuclease). Rats were administered intraduodenally an elemental liquid diet. Plasma CCK levels were raised to levels comparable to physiological postprandial levels either by intraduodenal perfusion with soybean trypsin inhibitor (SBTI) (6.9 +/- 1.0 pM, n = 8) or by continuous intravenous infusion with cholecystokinin octapeptide (CCK-8, 6.0 +/- 0.9 pM, n = 6). SBTI infusion resulted in fivefold increases in trypsinogen I and chymotrypsinogen B mRNA levels after 48 h. In contrast SBTI infusion had no effect on amylase mRNA levels and led to a decrease in ribonuclease mRNA levels to approximately 50% of control after 48 h. Intravenous infusion with CCK-8 for 24 h resulted in plasma levels of CCK comparable to those obtained with SBTI and had similar effects on digestive enzyme mRNA levels. These data suggested that SBTI acted via its ability to raise plasma CCK levels. To further test the specificity of these effects, animals were infused intraduodenally with the specific CCK receptor antagonist L364,718. Although the antagonist itself had no effect on digestive enzyme mRNA levels, antagonist treatment totally abolished the effects of both CCK infusion and SBTI treatment. These data therefore indicate that CCK regulates digestive enzyme gene expression at plasma concentrations comparable to physiological postprandial levels. Furthermore, the ability of SBTI infusion to increase plasma CCK accounts for its effects on pancreatic digestive enzyme mRNA levels.
Rosewicz
S
S
Department of Physiology, University of Michigan, Ann Arbor 48109.
Lewis
L D
LD
Wang
X Y
XY
Liddle
R A
RA
Logsdon
C D
CD
D000681:Amylases / Q000235:genetics; D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000097:blood*; D002918:Chymotrypsin / Q000235:genetics; D015342:DNA Probes; D020109:Devazepide; D005502:Food; D005786:Gene Expression Regulation / Q000187:drug effects*; D008297:Male; D009693:Nucleic Acid Hybridization; D010179:Pancreas / Q000201:enzymology*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D012260:Ribonucleases / Q000235:genetics; D012844:Sincalide / Q000494:pharmacology*; D014357:Trypsin / Q000235:genetics; D014360:Trypsin Inhibitor, Kunitz Soybean / Q000494:pharmacology*; D014361:Trypsin Inhibitors / Q000494:pharmacology*
D001570:Benzodiazepinones; D015342:DNA Probes; D012333:RNA, Messenger; D014361:Trypsin Inhibitors; D002766:Cholecystokinin; D014360:Trypsin Inhibitor, Kunitz Soybean; D012260:Ribonucleases; D000681:Amylases; D002918:Chymotrypsin; D014357:Trypsin; D020109:Devazepide; D012844:Sincalide